Effect of concomitantly administered drugs in the control of long term anticoagulant therapy. Quarterly Journal of Medicine 177: 63-73 (1976) . Pharmacokinetic aspects of the treatment of infections in the central nervous system Bacterial or fungal infections of the central nervous system (CNS) are conditions requiring prompt and adequate antibiotic treatment. The choice of antibiotics must be based on the antibacterial or antifungal spectrum of the drugs considered but also on their ability to penetrate into the cerebrospinal fluid (CSF) or the brain tissue. As pointed out in three recent reviews (Barling & Selkon, 1978; de Louvois, 1978; Norrby, 1978) only few antibiotics are capable of entering the CSF in therapeutic concentrations. The brain tissue is even more difficult to penetrate.
The first important consideration when dealing with drugs used for treatment of purulent meningitis or brain abscesses is the barriers which have to be passed before an antibiotic can reach the infectious focus. It is a common mistake to use the concept of a blood-brain barrier denoting both the blood-CSF barrier and the true blood-brain barrier. These two barriers differ vastly from each other. The blood-CSF barrier consists of the epithelial cells lining the choroid plexus while the blood-brain barrier is composed of the end capillaries in the brain tissue and their surrounding layers of glia cells. An example of the differences between the two barriers is cephalothin which has a lower capacity than most other P-lactam antibiotics to enter the CSF (Vianna & Kaye, 1967; Lerner, 1969) but which penetrates better than most Plactams into normal brain tissue (Kramer, Griffith & Campbell, 1969) . The opposite relation, i.e. better penetration into the CSF than into brain tissue has been reported with sulphamethoxazole and trimethoprim (Boger & Gavin, 1960; Craig & Kunin, 1973; Fries, Keuth & Braun, 1975) . It is not possible therefore, to extrapolate CSF pharmacokinetic data to brain tissue or vice versa. Moreover, there might be considerable differences between CSF and brain tissue with regard to changes in the penetrability into the two compartments when infection is present. While the penetration of antibiotics over the blood-CSF barrier is considerably increased by meningeal inflammation, the penetration into brain tissue seems to be enhanced by an acute inflammatory reaction but reduced by the formation of fibrin capsules around abscesses.
Several factors are of importance in drug penetration through the blood-CSF barrier. The degree of protein binding is of limited importance for the penetration of an antibiotic to shallow compartments but seems to influence the CSF penetration to a considerable extent as pointed out by Garrod & O'Grady (1971) . The lipid solubility of nonionised molecules of an antibiotic at physiological pH will influence CSF penetration as demonstrated for the tetracyclines (Barza et al., 1975) . Notably, lipophilicity is of no importance for antibiotics with pK, different from the physiological pH since more than 90 % of the molecules are ionised already at a pH-difference of one pH-unit above or below the pK.. The possibilities to utilize the lipophilicity depend to a large extent on the pH-gradient between blood and CSF. As demonstrated by Rail, Stabenau & Zubrud (1959) , the CSF penetration of sulphadiazine can be decreased significantly by inducing acidosis in dogs, thus decreasing the pHgradient In man the difference between the pH of plasma and that of CSF is approximately 0-1 pH-unit. A metabolic alkalosis will increase the gradient and it is also increased in cases of acute bacterial meningitis by the lowered pH in CSF caused by bacterial metabolism. Thus, there is normally an increased penetration of some antibiotics into CSF due to an increased pH-gradient.
Even if protein binding and lipid solubility influence the penetrability of antibiotics into the CSF, inflammation of the meninges is by far the most important factor. Almost all antibiotics enter the CSF more readily when the meninges are inflamed and with many antibiotics the CSF concentrations increase from almost nil in absence of inflammation to therapeutic concentrations when meningitis is present The most important clinical consequence of the different penetrability of the blood-CSF barrier at various stages of inflammation is that the dose used during the convalescent phase of a meningitis must be higher than during the acute phase due to the rapid healing of the blood-CSF barrier. To stop parenteral treatment with high doses in favour of oral treatment with lower doses when the patient is recovering seems meaningless unless there is an infectious focus outside theCNS.
When an antibiotic has managed to enter the cerebro-spinal space there are some important aspects on its transportation within that space. Firstly, CSF is produced in an amount of 500 to 600 ml per day and constantly eliminated to maintain a normal CSF volume of about 150 ml in the adult. The transportation of CSF is from the cisterna magna via the basal cisterns to the subarachnoid space. An important consequence of the flow direction is that administration of drugs in the lumbar space results in high local concentrations but in almost no concentrations in the basal cisterns and the cerebral ventricles. Moellering & Fisher (1972) demonstrated that gentamicin administered in the lumbar space gave no measurable ventricular concentrations. Clinically, Kaiser & McGee (1975) could demonstrate that intralumbar gentamicin did not increase the survival in neonatal meningitis compared to systemic gentamicin treatment while direct intraventricular administration was benefitial.
The third step in the pharmacokinetics of an antibiotic in CSF is its elimination from CSF. Since all antibiotics tend to accumulate in the CSF with repeated doses it seems reasonable to assume that the half life of an antibiotic in CSF is longer than that in serum. As a consequence of that, CSF concentrations should not be assayed after single doses only but after repeated administrations. Moreover, the peak CSF concentration of an antibiotic is recorded later than the peak serum concentraion. CSF samples for assay should therefore be drawn 1-5 to 3 h after parenteral administration. In many cases the slow elimination of antibiotics from the CSF results in an accumulation. However, there is also a possibility of the existence of active transport mechanisms enhancing the elimination of some antibiotics from the CSF. Several studies have demonstrated that benzylpenicillin is actively transported out of CSF and that the transportation can take place against a concentration gradient (Dixon, Owens & Rail, 1969; Fishman, 1966; Pollay, 1974) . Probenicid can inhibit the transportation both in animals and man (Dewhurst, 1969; Spector & Lorenzo, 1974) . Thus, administration of probenicid concurrently with antibiotics might offer a way of achieving higher CSF concentrations.
While several controlled studies on the penetration of antimicrobial agents into the CSF are available, very few studies have been published on the importance of pharmacokinetic variables on the penetration into brain tissue and brain abscesses. From the large amount of scattered data and from some larger studies (Kramer, Griffith & Campbell, 1969; de Louvois & Hurley, 1976) it can be concluded that clindamycin, fusidic acid, metronidazole and chloramphenicol are drugs which easily penetrate into brain tissue and brain abscesses. These drugs have in common that they are highly lipophilic, low protein bound and have low molecular weight Metronidazole and chloramphenicol appear to be concentrated in brain tissue, a phenomenon which has not yet been explained. Irrespective of the concentrations obtained, surgical intervention is also usually necessary. Black, Graybill & Charache (1973) demonstrated that although concentrations exceeding the minimal inhibitory concentrations of the causative anents were found in pus from brain abscesses, there were still many viable bacteria present, indicating that the pus inhibited the activity of the antibiotics tested. It can be concluded that few antibiotics are available for treatment of brain abscess and that they merely serve as support for surgical treatment. Chloramphenicol still seems to be the drug of choice for treatment of this serious condition. The esters of erythromycin Since its discovery in 1952 the macrolide antibiotic erythromycin has been shown to be active against a variety of Gram-positive cocci and bacilli, some Gram-negative organisms, and also Bacteroides spp., Treponema pallidum, Chlamydiae, Mycoplasma pneumoniae and the Legionnaires' disease bacillus LegioneUa pneumophila. Erythromycin is useful primarily for respiratory tract infections, streptococcal tonsillopharyngitis, sinusitis, otitis media, acute bronchitis and primary atypical pneumonia, and has been used for a variety of other infections.
RAGNAR NORRBY
The antibacterial spectrum of erythromycin is similar to that of the penicillins. However for reasons partly historical, partly related to the low incidence of bacterial resistance to erythromycin, but for the most part unknown, erythromycin is popularly considered as a 'second choice' drug to be used only when penicillin therapy is considered inappropriate.
Due to the instability of erythromycin in acidic media, oral dosages are presented in a variety of coated formulations designed to delay drug dissolution until it reaches the relatively alkaline small bowel. However such formulations have been associated with imperfect absorption and the literature contains examples of variable circulating antibiotic levels, ranging from adequate to zero. Most of these have been single dose studies and it is claimed that consistently inadequate absorption in 'poor absorbers' does not occur with repeated doses (Triggs & Neaverson, 1973 ).
An alternative approach to the problem of erythromycin stability has been the preparation of acid stable esters and ester salts, the most commonly prescribed being the 2' ethyl succinate and the lauryl sulphate salt of the 2' propionyl ester (estolate). Other esters of erythromycin have been described recently (Sinkula, 1974; Banaszek, 1969; Martin, 1972) but, to the writer's knowledge, none of these has resulted in either superior absorption or antibacterial activity.
The existing 2' esters of erythromycin have the advantage over the free base and its salts in that they are less water soluble, less acid labile, form a stable suspension in water, and are tasteless, compared to the bitter taste of unesterified drug. They thus provide a stable dosage form ideal for paediatric therapy.
Both the ethyl succinate and the estolate are well absorbed from oral doses. It is well established that, for a given dose size, erythromycin estolate gives rise to higher, more prolonged, and generally more reproducible circulating levels of apparent antibiotic activity than other erythromycin dosage forms. However, the esters of erythromycin have been suggested by Tardrew (1969) to be bacterially inactive until hydrolyzed back to the free base. The estolate hydrolyses in the body at a slower rate than the ethyl succinate, and circulating antibiotic levels from dosed estolate comprise 70 to 80% unchanged ester and only 20 to 30% of the base. With the more rapidly hydrorysed ethyl succinate, circulating levels comprise approximately 45 % ester and 55% base (Bechtol, 1976) .
Interpretation of the higher circulating levels obtained from dosed estolate is further complicated by the observations of Wiegand & Chun (1972) that the ester is 96 to 98% bound to plasma proteins compared to 80 to 90 % for the base, although other reports have disagreed with these values. Increased binding of the estolate to plasma proteins was considered by Wiegand and Chun to give rise to less extensive tissue penetration of this drug form compared to the base, and some tissue level data were presented to support this. Other studies have shown however, that erythromycin estolate distributes into some tissues more efficiently than other drug forms, giving rise to superior levels of 'antibiotic' in tonsil tissue, middle ear fluid in otitis media, and aqueous humour. Although these levels probably consist of both the ester and the free base, one cannot exclude the possibility that bacterial esterases may be capable of regenerating the active free base within the bacterial cell. One might ask skeptically whether any clinical evidence exists to support this, and the evidence is indeed not overwhelming. However, a number of independent studies have shown that erythromycin estolate has equivalent clinical effect at lower dose levels compared to other erythromycin forms in the treatment of streptococcal pharyngitis
